drugset
drugset / Trial / NCT06585644

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

NCT06585644 ↗

Phase 2 Not yet recruiting 44 enrolled Shanghai Pulmonary Hospital, Shanghai, China
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.

Timeline

Start
2024-10-01
Primary completion
2025-11-01
Completion
2030-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg —
Subject Firmonertinib Small molecule 80 mg —

Indications

non-small cell lung carcinoma